Atogepant- Allergan

Drug Profile

Atogepant- Allergan

Alternative Names: AGN 241689; MK 8031

Latest Information Update: 14 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck AG
  • Developer Allergan
  • Class Antimigraines; Monoclonal antibodies; Piperidines; Pyridines; Pyrroles; Small molecules; Spiro compounds
  • Mechanism of Action Calcitonin gene-related peptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Migraine

Most Recent Events

  • 14 Sep 2017 Chemical structure information added
  • 01 Sep 2016 Phase-II/III clinical trials in Migraine (Prevention) in USA (PO)
  • 24 Aug 2016 Allergan plans a phase II/III trial for Migraine (Prevention) in USA (NCT02848326)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top